Phase <scp>II</scp> study of <scp>IRInotecan</scp> treatment after <scp>COmbined</scp> chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of <scp>IRICO</scp> study
Thoracic cancer